CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
Bharat Forge Ltd. 25/07/20241,593.85952.3007/04/2025 -40.25% 256 days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Coronavirus stings the markets

DSIJ Intelligence-3 0 978 Article rating: 5.0

The markets witnessed a massive bout of volatility last week and we believe that the last week’s volatility was just a trailer! As we enter the Budget week, markets are likely to witness an elevated volatility. The fresh week is expected to start on a scary note for the markets as investors across the globe are rattled by the spread of coronavirus outbreak.

Weak start in offing

DSIJ Intelligence-3 0 594 Article rating: 5.0

Welcome to the last trading session of the week! In the last trading sessions, markets put up a good show, however, it rallied due to short-covering and bulls may not continue yesterday’s momentum since cues from global markets are subdued.

Alembic Pharmaceuticals receive USFDA nod for Fenofibrate tablets

DSIJ Intelligence 0 1827 Article rating: 5.0

Alembic Pharmaceuticals announced that it has received final approval from US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Fenofibrate tablets USP, 54 mg and 160 mg. The approved ANDA is therapeutically equivalent to the Reference Listed Drug (RLD) product Tricor tablets, 54 mg and 160 mg of AbbVie Inc.

Indian markets likely to open on cautious note

DSIJ Intelligence-3 0 747 Article rating: 5.0

In the early trend, SGX Nifty is trading above the dotted lines indicating a flat to positive opening for Indian markets. However, cautious would continue to prevail on the D-Street as the global cues could play a spoil sport as the markets participants assess China virus impact. At the time of writing, SGX Nifty was up by 6 points at 12,146 levels.

ICICI Lombard gets regulatory nod to pilot 5 proposals

DSIJ Intelligence 0 1913 Article rating: 3.3

ICICI Lombard announced that it has received a green signal to pilot five innovative applications and programs in its health and motor portfolio under the Insurance Regulatory and Development Authority of India (IRDAI) introduced Sandbox project. The company is to pilot the five proposals from February 1, 2020 to July 31, 2020.

Index trend and stocks in action on January 22, 2020

DSIJ Intelligence-3 0 1300 Article rating: 5.0

We expect the buying interest to emerge around the 12,045-12,120 levels as it is a crucial support level for the index in the near term. On the higher side, the level of 12,230-12,250 is likely to act as a resistance area. Stocks in news: Biocon, Glenmark Pharmaceuticals, Bharti Airtel, PEL, ZF Steering Gear India, Vodafone Idea.

RSS
First365366367368370372373374Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR